Shuplock Jacqueline M, Smith Andrew H, Owen Jill, Van Driest Sara L, Marshall Matt, Saville Benjamin, Xu Meng, Radbill Andrew E, Fish Frank A, Kannankeril Prince J
From the Thomas P. Graham Jr. Division of Pediatric Cardiology (J.M.S., A.H.S., J.O., A.E.R., F.A.F., P.J.K.), Division of Pediatric Critical Care Medicine (A.H.S.), and Division of General Pediatrics (S.L.V.D.), Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN; Department of Pharmaceutical Services at Vanderbilt University Medical Center, Nashville, TN (M.M.); and Department of Biostatistics at Vanderbilt University School of Medicine, Nashville, TN (B.S., M.X.).
Circ Arrhythm Electrophysiol. 2015 Jun;8(3):643-50. doi: 10.1161/CIRCEP.114.002301. Epub 2015 Apr 15.
Dexmedetomidine is commonly used after congenital heart surgery and may be associated with a decreased incidence of postoperative tachyarrhythmias. Using a large cohort of patients undergoing congenital heart surgery, we examined for an association between dexmedetomidine use in the immediate postoperative period and subsequent arrhythmia development.
A total of 1593 surgical procedures for congenital heart disease were performed. Dexmedetomidine was administered in the immediate postoperative period after 468 (29%) surgical procedures. When compared with 1125 controls, the group receiving dexmedetomidine demonstrated significantly fewer tachyarrhythmias (29% versus 38%; P<0.001), tachyarrhythmias receiving intervention (14% versus 23%; P<0.001), bradyarrhythmias (18% versus 22%; P=0.03), and bradyarrhythmias receiving intervention (12% versus 16%; P=0.04). After propensity score matching with 468 controls, the arrhythmia incidence between groups became similar: tachyarrhythmias (29% versus 31%; P=0.66), tachyarrhythmias receiving intervention (14% versus 17%; P=0.16), bradyarrhythmias (18% versus 15%; P=0.44), and bradyarrhythmias receiving intervention (12% versus 9%; P=0.17). After excluding controls exposed to dexmedetomidine at a later time in the hospitalization, dexmedetomidine was associated with increased odds of bradyarrhythmias receiving intervention (odds ratio, 2.18; 95% confidence interval, 1.02-4.65). Furthermore, there was a dose-dependent increase in the odds of bradyarrhythmias (odds ratio, 1.04; 95% confidence interval, 1.01-1.07) and bradyarrhythmias receiving intervention (odds ratio, 1.05; 95% confidence interval, 1.01-1.08).
Although dexmedetomidine exposure in the immediate postoperative period is not associated with a clinically meaningful difference in the incidence of tachyarrhythmias after congenital heart surgery, it may be associated with increased odds of bradyarrhythmias.
右美托咪定常用于先天性心脏病手术后,可能与术后快速性心律失常的发生率降低有关。我们使用一大群接受先天性心脏病手术的患者,研究术后即刻使用右美托咪定与随后心律失常发生之间的关联。
共进行了1593例先天性心脏病手术。468例(29%)手术术后即刻给予右美托咪定。与1125例对照相比,接受右美托咪定治疗的组快速性心律失常显著较少(29%对38%;P<0.001),接受干预的快速性心律失常(14%对23%;P<0.001),缓慢性心律失常(18%对22%;P=0.03),以及接受干预的缓慢性心律失常(12%对16%;P=0.04)。在与468例对照进行倾向评分匹配后,两组间心律失常发生率变得相似:快速性心律失常(29%对31%;P=0.66),接受干预的快速性心律失常(14%对17%;P=0.16),缓慢性心律失常(18%对15%;P=0.44),以及接受干预的缓慢性心律失常(12%对9%;P=0.17)。在排除住院后期接触右美托咪定的对照后,右美托咪定与接受干预的缓慢性心律失常几率增加相关(比值比,2.18;95%置信区间,1.02 - 4.65)。此外,缓慢性心律失常几率(比值比,1.04;95%置信区间,1.01 - 1.07)和接受干预的缓慢性心律失常几率(比值比,1.05;95%置信区间,1.01 - 1.08)呈剂量依赖性增加。
尽管先天性心脏病手术后即刻使用右美托咪定与快速性心律失常发生率的临床意义差异无关,但可能与缓慢性心律失常几率增加有关。